Uniunea Europeană - română - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - medicamente pentru tratamentul bolilor osoase - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allphamed pharbil arzneimittel gmbh - germania - burosumabum - sol. inj. - 10mg/ml - med. ce influenteaza in structura osoasa si mineralizare alte med. ce influenteaza structura osoasa si mineralizarea

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allphamed pharbil arzneimittel gmbh - germania - burosumabum - sol. inj. - 20mg/ml - med. ce influenteaza in structura osoasa si mineralizare alte med. ce influenteaza structura osoasa si mineralizarea

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allphamed pharbil arzneimittel gmbh - germania - burosumabum - sol. inj. - 30mg/ml - med. ce influenteaza in structura osoasa si mineralizare alte med. ce influenteaza structura osoasa si mineralizarea